Sfoglia per Autore
Anti-Gm1 And Anti-Sulfatide Antibodies In Polyneuropathies. Threshold Titers And Accuracy
2001-01-01 G.L. ISOARDO; B. FERRERO; P. BARBERO; A. CUCCI; A. OGGERO; A. PIPIERI; A. RICCI; E. VERDUN; B. BERGAMASCO; L. DURELLI
Is it possible to reduce the dose of interferon (IFN) beta in MS patients with a prolonged MRI-confirmed absence of disease activity?
2002-01-01 P. Barbero; A. Pipieri; E. Verdun; M. Bergui; G. Isoardo; A. Bosio; M. Clerico; A. Cucci; A. Ricci; B. Bergamasco; L. Durelli
Mitoxantrone safety in secondary progressive Multiple Sclerosis patients
2003-01-01 E. VERDUN; P. BARBERO; L. MANNESCHI; G. SALEMI; A. PIPIERI; M. CLERICO; A. RICCI; A. CUCCI; G. CUCCIA; E. CAMMARATA; G. SAVETTIERI; I. PESCI; E. MONTANARI; B. BERGAMASCO; L. DURELLI
Long-term evaluation of safety and efficacy of mitoxantrone therapy in secondary progressive Multiple Sclerosis patients.
2003-01-01 L. MANNESCHI; E. VERDUN; P. BARBERO; G. SALEMI; A. PIPIERI; M. CLERICO; I. PESCI; A. RICCI; A. CUCCI; F. BATTAGLIERI; E. CAMMARATA; G. SAVETTIERI; B. BERGAMASCO; E. MONTANARI; L. DURELLI
MX protein and neutralizing interferon antibodies in relapsing remitting multiple sclerosis patients treated with interferon beta-1b: correlation with clinical and mri efficacy
2003-01-01 A.RICCI; M.A.CUCCI; E. VERDUN; M. CLERICO; A. PIPIERI; P. BARBERO; L. DURELLI
Increasing dose of ifn beta 1b in ms patients: preliminary nab results from the optims study.
2003-01-01 VERDUN E; A. RICCI; P. BARBERO; M. CLERICO; A. PIPIERI; M. BERGUI; E. VERSINO; A. CUCCI; J.J. ZHONG; L. DURELLI; AND OPTIMS STUDY GROUP
Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients.
2003-01-01 A. PIPIERI; P. BARBERO; M. CLERICO; E. VERDUN; E. VERSINO; A. CUCCI; E. PUCCI; E. CARTECHINI; L. MANNESCHI; G. GIULIANI; E. MONTANARI; L. DURELLI
La dose ottimale di interferone beta: studio preliminare sulla tolleranza della dose di 375 microgrammi di interferone beta-1b
2003-01-01 E. VERDUN; P. BARBERO. A. RICCI; M. CLERICO; A. PIPIERI; A. CUCCI; M. IMPAGLIA; L. DURELLI
Secondary progressive (sp) ms: immunological effects of intravenous immunoglobuln g (ivig) therapy
2003-01-01 A.RICCI; A. OGGERO; R. CLERICI; A. CUCCI; M. CLERICO; E. VERDUN; A. PIPIERI; E. SCARPINI; L. DURELLI
NAB titre in patients treated with different doses of ifn beta-1b: preliminary results from the optims study.
2003-01-01 A. RICCI; E. VERDUN; P. BARBERO; A. CUCCI; M. CLERICO; A. PIPIERI; E. VERSINO; M. BERGUI; J.J. ZHONG; L. DURELLI; ON BEHALF OF THE OPTIMS STUDY GROUP
Evaluation of mitochondrial manganese in leukocyte of multiple sclerosis patients.
2003-01-01 M.A. CUCCI; A. NONNATO; P. BARBERO; L. BRANCIFORTE; A. RICCI; E. VERDUN; M. CLERICO; A. PIPIERI; A. CAROPRESO; G. PESCARMONA; L. DURELLI
Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD).
2003-01-01 M. CLERICO; E. ROTA; A. RICCI; E. VERDUN; P. BARBERO; A. PIPIERI; A. CUCCI; L. GIORDANO; L. DURELLI
Autoimmunity profile in interferon beta-1a treated Multiple Sclerosis patients. The AUPRIN Study: comparison of 2 different dosages of subcutaneous interferon beta-1a
2004-01-01 E. VERDUN; A. RICCI; M.A. CUCCI; P. BARBERO; A. PIPIERI; M. CLERICO; L. GIORDANO; L. DELFICO; G. AIMO; T. M. PACIELLO; T. TASSINARI; L. MOTTI; A. REGGIO; L. DURELLI; THE AUPRIN STUDY GROUP
Autoimmunity profile in interferon beta- 1a treated multiple sclerosis patients. the auprin study: comparision of 2 different dosage of subcutaneous interferon-beta 1a.
2004-01-01 E. VERDUN; A. RICCI; M.A. CUCCI; P. BARBERO; A. PIPIERI; M. CLERICO; L. GIORDANO; L. DELFICO; T. TASSINARI; L. MOTTI; M. PACIELLO; A. REGGIO; G. AIMO; L. DURELLI; ON BEHALF OF THE AUPRIN STUDY GROUP
A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study.
2004-01-01 E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; L. GIORDANO; L. DURELLI
Mxa protein, interleukin-10 (il-10) and neutralizing antibody (nab) in relapsing- remitting (rr) multiple sclerosis (ms) patients treated with different doses of inteferon (ifn) beta- 1b.
2004-01-01 A. RICCI; M.A. CUCCI; L. DURELLI
Mxa protein, interleukin-10 and neutralising antibody in MS patients treated with different doses of Interferon-Beta-1b
2004-01-01 A. RICCI; M. CLERICO; M.A. CUCCI; P. BARBERO; E. VERDUN; A. PIPIERI; L. GIORDANO; L. DURELLI; ON BEHALF OF THE OPTIMS STUDY GROUP
High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study
2004-01-01 BARBERO P; VERDUN E; BERGUI M; PIPIERI A; CLERICO M; CUCCI A; RICCI A; BERGAMASCO B; DURELLI L
IFN beta-1b in multiple sclerosis: comparing two different doses (the Optims Study).
2004-01-01 E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; M. BERGUI; E. VERSINO; L. GIORDANO; M. ZAFFARONI; E. MONTANARI; G. GIULIANI; L. DURELLI; AND THE OPTIMS STUDY GROUP
High-dose interferon-beta-1b (500 mcg every-other-day, subcutaneously) treatment in MS patients. Long-term evaluation and longitudinal comparison with preceding treatment with lower IFN beta dose
2004-01-01 P. Barbera; A. Pipieri; E. Verdun; M. Clerico; A. Ricci; M. A. Cucci; L. Giordano; E. Cartechini; G. Giuliani; E. Montanari; M. Bergui; L. Durelli
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Anti-Gm1 And Anti-Sulfatide Antibodies In Polyneuropathies. Threshold Titers And Accuracy | 2001 | G.L. ISOARDO; B. FERRERO; P. BARBERO; A. CUCCI; A. OGGERO; A. PIPIERI; A. RICCI; E. VERDUN; B. BERGAMASCO; L. DURELLI | |
| Is it possible to reduce the dose of interferon (IFN) beta in MS patients with a prolonged MRI-confirmed absence of disease activity? | 2002 | P. Barbero; A. Pipieri; E. Verdun; M. Bergui; G. Isoardo; A. Bosio; M. Clerico; A. Cucci; A. Ricci; B. Bergamasco; L. Durelli | |
| Mitoxantrone safety in secondary progressive Multiple Sclerosis patients | 2003 | E. VERDUN; P. BARBERO; L. MANNESCHI; G. SALEMI; A. PIPIERI; M. CLERICO; A. RICCI; A. CUCCI; G. CUCCIA; E. CAMMARATA; G. SAVETTIERI; I. PESCI; E. MONTANARI; B. BERGAMASCO; L. DURELLI | |
| Long-term evaluation of safety and efficacy of mitoxantrone therapy in secondary progressive Multiple Sclerosis patients. | 2003 | L. MANNESCHI; E. VERDUN; P. BARBERO; G. SALEMI; A. PIPIERI; M. CLERICO; I. PESCI; A. RICCI; A. CUCCI; F. BATTAGLIERI; E. CAMMARATA; G. SAVETTIERI; B. BERGAMASCO; E. MONTANARI; L. DURELLI | |
| MX protein and neutralizing interferon antibodies in relapsing remitting multiple sclerosis patients treated with interferon beta-1b: correlation with clinical and mri efficacy | 2003 | A.RICCI; M.A.CUCCI; E. VERDUN; M. CLERICO; A. PIPIERI; P. BARBERO; L. DURELLI | |
| Increasing dose of ifn beta 1b in ms patients: preliminary nab results from the optims study. | 2003 | VERDUN E; A. RICCI; P. BARBERO; M. CLERICO; A. PIPIERI; M. BERGUI; E. VERSINO; A. CUCCI; J.J. ZHONG; L. DURELLI; AND OPTIMS STUDY GROUP | |
| Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients. | 2003 | A. PIPIERI; P. BARBERO; M. CLERICO; E. VERDUN; E. VERSINO; A. CUCCI; E. PUCCI; E. CARTECHINI; L. MANNESCHI; G. GIULIANI; E. MONTANARI; L. DURELLI | |
| La dose ottimale di interferone beta: studio preliminare sulla tolleranza della dose di 375 microgrammi di interferone beta-1b | 2003 | E. VERDUN; P. BARBERO. A. RICCI; M. CLERICO; A. PIPIERI; A. CUCCI; M. IMPAGLIA; L. DURELLI | |
| Secondary progressive (sp) ms: immunological effects of intravenous immunoglobuln g (ivig) therapy | 2003 | A.RICCI; A. OGGERO; R. CLERICI; A. CUCCI; M. CLERICO; E. VERDUN; A. PIPIERI; E. SCARPINI; L. DURELLI | |
| NAB titre in patients treated with different doses of ifn beta-1b: preliminary results from the optims study. | 2003 | A. RICCI; E. VERDUN; P. BARBERO; A. CUCCI; M. CLERICO; A. PIPIERI; E. VERSINO; M. BERGUI; J.J. ZHONG; L. DURELLI; ON BEHALF OF THE OPTIMS STUDY GROUP | |
| Evaluation of mitochondrial manganese in leukocyte of multiple sclerosis patients. | 2003 | M.A. CUCCI; A. NONNATO; P. BARBERO; L. BRANCIFORTE; A. RICCI; E. VERDUN; M. CLERICO; A. PIPIERI; A. CAROPRESO; G. PESCARMONA; L. DURELLI | |
| Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD). | 2003 | M. CLERICO; E. ROTA; A. RICCI; E. VERDUN; P. BARBERO; A. PIPIERI; A. CUCCI; L. GIORDANO; L. DURELLI | |
| Autoimmunity profile in interferon beta-1a treated Multiple Sclerosis patients. The AUPRIN Study: comparison of 2 different dosages of subcutaneous interferon beta-1a | 2004 | E. VERDUN; A. RICCI; M.A. CUCCI; P. BARBERO; A. PIPIERI; M. CLERICO; L. GIORDANO; L. DELFICO; G. AIMO; T. M. PACIELLO; T. TASSINARI; L. MOTTI; A. REGGIO; L. DURELLI; THE AUPRIN STUDY GROUP | |
| Autoimmunity profile in interferon beta- 1a treated multiple sclerosis patients. the auprin study: comparision of 2 different dosage of subcutaneous interferon-beta 1a. | 2004 | E. VERDUN; A. RICCI; M.A. CUCCI; P. BARBERO; A. PIPIERI; M. CLERICO; L. GIORDANO; L. DELFICO; T. TASSINARI; L. MOTTI; M. PACIELLO; A. REGGIO; G. AIMO; L. DURELLI; ON BEHALF OF THE AUPRIN STUDY GROUP | |
| A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study. | 2004 | E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; L. GIORDANO; L. DURELLI | |
| Mxa protein, interleukin-10 (il-10) and neutralizing antibody (nab) in relapsing- remitting (rr) multiple sclerosis (ms) patients treated with different doses of inteferon (ifn) beta- 1b. | 2004 | A. RICCI; M.A. CUCCI; L. DURELLI | |
| Mxa protein, interleukin-10 and neutralising antibody in MS patients treated with different doses of Interferon-Beta-1b | 2004 | A. RICCI; M. CLERICO; M.A. CUCCI; P. BARBERO; E. VERDUN; A. PIPIERI; L. GIORDANO; L. DURELLI; ON BEHALF OF THE OPTIMS STUDY GROUP | |
| High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study | 2004 | BARBERO P; VERDUN E; BERGUI M; PIPIERI A; CLERICO M; CUCCI A; RICCI A; BERGAMASCO B; DURELLI L | |
| IFN beta-1b in multiple sclerosis: comparing two different doses (the Optims Study). | 2004 | E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; M. BERGUI; E. VERSINO; L. GIORDANO; M. ZAFFARONI; E. MONTANARI; G. GIULIANI; L. DURELLI; AND THE OPTIMS STUDY GROUP | |
| High-dose interferon-beta-1b (500 mcg every-other-day, subcutaneously) treatment in MS patients. Long-term evaluation and longitudinal comparison with preceding treatment with lower IFN beta dose | 2004 | P. Barbera; A. Pipieri; E. Verdun; M. Clerico; A. Ricci; M. A. Cucci; L. Giordano; E. Cartechini; G. Giuliani; E. Montanari; M. Bergui; L. Durelli |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile